// App-Quantinova.ai

FRI0141 : CHARACTERIZATION OF SERIOUS INFECTIONS WITH UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS

Researchers

Presenter

  • K. Winthrop

Principal Investigators

  • L. Calabrese

  • F. Van den Bosch

  • K. Yamaoka

  • C. Selmi

  • Y. Song

  • B. Hendrickson

  • I. Lagunes-Galindo

  • I. Mcinnes

Medical Centers

  • Oregon Health and Science University, Division of Infectious Diseases, Portland, United States of America

  • Cleveland Clinic, Cleveland, OH, United States of America

  • Ghent University and VIB Center for Inflammation Research, Ghent, Belgium

  • Kitasato University School of Medicine, Department of Rheumatology and Infectious Diseases, Sagamihara, Japan

  • Humanitas Research Hospital & Humanitas University,Milan,Italy

  • University of Glasgow, Glasgow, United Kingdom

Locations

  • United States

  • Belgium

  • Japan

  • Italy

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • Plasminogen Activator, Urokinase

Drug/Treatment

  • Methotrexate

  • ABT-494

  • Adalimumab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Bristol-Myer Squibb

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved